Cargando…

SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia

Detalles Bibliográficos
Autores principales:	Mellinghoff, Sibylle C., Mayer, Leonie, Robrecht, Sandra, Weskamm, Leonie M., Dahlke, Christine, Gruell, Henning, Schlotz, Maike, Vanshylla, Kanika, Schlößer, Hans A., Thelen, Martin, Fink, AnnaMaria, Fischer, Kirsten, Klein, Florian, Addo, Marylyn M., Eichhorst, Barbara, Hallek, Michael, Langerbeins, Petra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521220/ https://www.ncbi.nlm.nih.gov/pubmed/35734927 http://dx.doi.org/10.3324/haematol.2022.280982

Ejemplares similares

SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia
por: Mellinghoff, Sibylle C., et al.
Publicado: (2021)

Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19
por: Mellinghoff, Sibylle C., et al.
Publicado: (2021)

Flow cytometric protocol to characterize human memory B cells directed against SARS-CoV-2 spike protein antigens
por: Weskamm, Leonie M., et al.
Publicado: (2022)

2343. SARS-CoV-2 Spike Conformation Essentially Influences Vaccine Immunogenicity – Results from Two Clinical Phase I Trials of the Vector Vaccine Candidates MVA-SARS-2-S and MVA-SARS-2-ST
por: Fathi, Anahita, et al.
Publicado: (2023)

Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
por: Weskamm, Leonie M., et al.
Publicado: (2022)

Correlates of Vaccine-Induced Protection against SARS-CoV-2
por: Koch, Till, et al.
Publicado: (2021)

72/m mit Zufallsbefund einer Lymphozytose: Vorbereitung auf die Facharztprüfung: Fall 34
por: Langerbeins, Petra, et al.
Publicado: (2022)

COVID‐19 complicated by parainfluenza co‐infection in a patient with chronic lymphocytic leukemia
por: Langerbeins, Petra, et al.
Publicado: (2020)

Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody
por: Meijers, Matthijs, et al.
Publicado: (2021)

Antibody-mediated neutralization of SARS-CoV-2
por: Gruell, Henning, et al.
Publicado: (2022)

Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1
por: LaMont, Colin, et al.
Publicado: (2022)

Invasive Aspergillosis in Patients Treated With Ibrutinib
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Digital PCR to quantify ChAdOx1 nCoV-19 copies in blood and tissues
por: Badbaran, Anita, et al.
Publicado: (2021)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

COVID-19 in patients with hematologic malignancy
por: Langerbeins, Petra, et al.
Publicado: (2022)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults
por: Ercanoglu, Meryem Seda, et al.
Publicado: (2022)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
por: Gruell, Henning, et al.
Publicado: (2022)

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
por: Vanshylla, Kanika, et al.
Publicado: (2021)

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
por: Fathi, Anahita, et al.
Publicado: (2019)

Sex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging Pathogens
por: Fathi, Anahita, et al.
Publicado: (2021)

CD34T+ Humanized Mouse Model to Study Mucosal HIV-1 Transmission and Prevention
por: Vanshylla, Kanika, et al.
Publicado: (2021)

Lactobacilli Expressing Broadly Neutralizing Nanobodies against HIV-1 as Potential Vectors for HIV-1 Prophylaxis?
por: Kalusche, Sarah, et al.
Publicado: (2020)

Evaluation of a Rapid Antigen Test To Detect SARS-CoV-2 Infection and Identify Potentially Infectious Individuals
por: Korenkov, Michael, et al.
Publicado: (2021)

Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG
por: Eberhardt, Kirsten Alexandra, et al.
Publicado: (2021)

Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults
por: Vanshylla, Kanika, et al.
Publicado: (2022)

Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
por: Tober-Lau, Pinkus, et al.
Publicado: (2022)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group
por: von Tresckow, Julia, et al.
Publicado: (2023)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020)

SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
por: Gruell, Henning, et al.
Publicado: (2022)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
por: Fürstenau, Moritz, et al.
Publicado: (2019)

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
por: Herling, Carmen D., et al.
Publicado: (2020)

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
por: Tober-Lau, Pinkus, et al.
Publicado: (2021)

Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
por: Schommers, Philipp, et al.
Publicado: (2020)

Immunological fingerprint in coronavirus disease-19 convalescents with and without post-COVID syndrome
por: Augustin, Max, et al.
Publicado: (2023)

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
por: Fürstenau, Moritz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8d7vj99i0fecsioj4cd88g24f8